November 11, 2025
Mark Cuban sends strong message on major Medicare change
See More
Media & News
In the News
August 8, 2025
Currax’s human-centric campaign sets an example for marketing weight loss drugs
See More
July 14, 2025
Need a DTC platform? Here’s how one company built its own. Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med.
See More
June 9, 2025
Currax CEO George Hampton Featured on Bloomberg Markets: Navigating Innovation and Access in Pharma
See More
April 15, 2025
Currax CEO on pharmacuetical tariffs, stockpiling and foreign production
See More
April 7, 2025
FierceMadness: AstraZeneca battles itself in Final Four of 2025 Drug Ad Tournament—VOTE NOW
See More
March 20, 2025
Currax gets FDA approval for second manufacturing site for oral weight loss drug
See More
March 14, 2025
High Price of GLP-1 Agents Tip Cost-Benefit Scale Unfavorably
See More
February 7, 2025
Considerations for Prescribing GLP-1s Get More Complicated
See More
January 10, 2025
PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials
See More
December 4, 2024
Watch the CONTRAVE® (naltrexone HCl/bupropion HCl) TV commercial w/ the track Don't Own Me.
See More
November 10, 2024
Why weight-loss drugs aren't covered by insurance
See More
October 30, 2024
Currax is benefitting from weight loss drug demand, says CEO George Hampton
See More
September 24, 2024
Currax, maker of weight loss drug Contrave, constructs campaign to educate on "food noise"
See More
August 26, 2024
Currax Sees Demand for Weight-Loss Drug Contrave Growing
See More
July 23, 2024
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
See More
May 23, 2024
Weight-loss drugs: How low costs, easy access change the game now
See More
April 24, 2024
Currax Pharmaceuticals CEO says the GLP-1 conversation isn’t one-size-fits-all
See More
March 29, 2024
Contrave mimics diet and exercise: George Hampton
See More
March 1, 2024
The obesity population in the U.S. is 95% untreated, says Currax CEO George Hampton
See More
January 29, 2024
Currax Pharmaceuticals CEO on North Carolina ending obesity drug coverage
See More
March 6, 2022
The Boss: If you were a toddler soccer champion, George Hampton wants to know
See MorePress Releases
Videos for Patients & Partners
Patient Access
Treating Obesity
Path to Coverage
Coverage
Welcome to Currax
Learn More About Currax
Media Inquiries
Please contact Hope Mueller, SVP, Corporate Development and Strategy, at [email protected] with any questions related to media stories or interview requests.